Results 151 to 160 of about 6,146 (182)

Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study [PDF]

Helen Tesfaye, Katherine M. Wang, Luke E. Zabotka, Deborah J. Wexler, Niklas Schmedt, Lisette Koeneman, Leo Seman, Julie M. Paik, Elisabetta Patorno   +8 more
openalex   +1 more source

Empagliflozin in Modern Diabetes Care: Future Directions in Patient Care

Mitali Dalwadi Kiran Sharma*
openalex   +1 more source

The Influence of the Concurrent Use of Catha edulis Forsk (Khat) and Empagliflozin on Dexamethasone-Induced Hyperglycemia in Rabbits

Albaser NA
openalex   +1 more source

Effects of empagliflozin and vildagliptin on cognitive impairment in a rat model induced by high-fat diet and low-dose streptozotocin

A.N. Hazar-Yavuz, M.A.Q.R. Khaled, O.T. Cilingir-Kaya   +2 more
openalex   +1 more source

Additional file 1 of Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial

Bassant M. Mahboub, Ayman Refaie, Sahar M. El-Haggar, Yasser Mostafa Hafez, Tarek M. Mostafa   +4 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Empagliflozin

Reactions Weekly, 2023
  +13 more sources

Empagliflozin

Reactions Weekly, 2021
  +8 more sources

Empagliflozin

Reactions Weekly
  +11 more sources

Empagliflozin

Reactions Weekly, 2022
  +4 more sources

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Nature Medicine, 2022
Adriaan A Voors, Christiane Angermann Angermann, John R Teerlink   +2 more
exaly